FearLess in Neuro-Oncology
Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The overarching goal of this project is to assess the feasibility, acceptability, and appropriateness of recruitment methods, target population, and a waitlist design to finalize the protocol of FearLess in primary malignant brain tumor patients and caregivers
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
⁃ Patients:
• Self-report a diagnosis of a primary malignant brain tumor (grade II-IV)
• \>2 weeks post-cranial resection or biopsy
• Elevated Fear of Recurrence Distress Rating
• Primarily English speaking
• \>/= 18 years of age at the time of enrollment
⁃ Caregivers:
• nonprofessional caregiver to a patient with a primary malignant brain tumor (grade II-IV)
• Elevated Fear of Recurrence Distress Rating
• Primarily English speaking
• \>/= 18 years of age at the time of enrollment
Locations
United States
Virginia
Virginia Commonwealth University
RECRUITING
Richmond
Contact Information
Primary
Mary Bridgman
LiveNOW@vcu.edu
804-628-6799
Time Frame
Start Date: 2025-06-24
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 112
Treatments
Experimental: Fearless Immediate Treatment Arm
FearLess is a newly developed, empirically-rooted, manualized psychological intervention consisting of an intake + 8 sessions delivered over a 12-week time period. It consists of weekly individual 60- to 90-minute virtual therapy sessions. FearLess will be delivered immediately following enrollment in this arm.
Other: FearLess Delayed Control Arm
FearLess is a newly developed, empirically-rooted, manualized psychological intervention consisting of an intake + 8 sessions delivered over a 12-week time period. It consists of weekly individual 60- to 90-minute virtual therapy sessions. In this arm, the FearLess intervention will begin following a 12-week no-treatment period.
Related Therapeutic Areas
Sponsors
Collaborators: National Brain Tumor Society, National Cancer Institute (NCI)
Leads: Virginia Commonwealth University